Selective treatment of multiple sclerosis.
Ropper
Allan H
AH
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D015815:Cell Adhesion Molecules / Q000037:antagonists & inhibitors*; D004359:Drug Therapy, Combination; D006801:Humans; D039441:Integrin alpha4; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000627:therapeutic use*; D007577:JC Virus; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D000069442:Natalizumab; D055502:Secondary Prevention
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015815:Cell Adhesion Molecules; D000069442:Natalizumab; D039441:Integrin alpha4; D016899:Interferon-beta; D000068556:Interferon beta-1a